Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
- Study Title
- Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
- Teva Identifier
- C38072-AS-30025 | 2015-000865-29
- ClinicalTrials.gov Identifier
- NCT02452190
- Study Status
- Completed
- Trial Condition(s)
- Asthma
- Interventions
- Drug: Reslizumab | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 12 Years and older
- Trial Duration
- September 28, 2015 - January 31, 2018
- Phase
- Phase 3